JPRN-UMIN000038901已完成未知
All-in-one gel anti-wrinkle effect : single blinded study - All-in-one gel anti-wrinkle effect
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 59years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Subjects with cosmetic allergies 2. Subjects who are pregnant or lactating 3. Subjects with inflamed or scraped skin on face 4. Subjects who are judged as unsuitable for the study by the investigator for the other reason
研究者
相似试验
已完成
1 期
Comparison between two injectable formulations of anti- cancer drug Pertuzumab by studying their blood levels and safety in healthy adult male subjectsCTRI/2023/06/054259CinnaGen Research and Production Company80
进行中（未招募）
1 期
A randomised, placebo-controlled, single-blind study to characterise the biomarker effects of the CSF-1 receptor antagonist JNJ-40346527 in participants with mild cognitive impairment.EUCTR2018-004149-17-GBniversity of Oxford / Clinical Trials and Research Governance54
尚未招募
4 期
A prospective, randomized, controlled, single blind clinical study of Shenqigui oral liquid for improving bone marrow suppression in patients with small cell lung cancer of Qi and yin defiGas-yin two impeved small cell lung cancerITMCTR2100004677Chengdu University of Traditional Chinese Medicine
未知
3 期
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIAJPRN-jRCT2080222813ovartis Pharma K.K.20
进行中（未招募）
不适用
A SINGLE-DOSE, OPEN-LABEL, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 50/6 HFA pMDI (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 50µg PLUS FORMOTEROL FUMARATE 6 µg ) USING THE AEROCHAMBER PLUS™ SPACER DEVICE VERSUS THE FREE COMBINATION OF BECLOMETHASONE HFA pMDI AND FORMOTEROL HFA pMDI AVAILABLE ON THE MARKET USING THE AEROCHAMBER PLUS™ SPACER DEVICE IN ASTHMATIC CHILDREAsthmatic children, aged 5-11, with a forced expiratory volume in one second (FEV1) > 70% of predicted values.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2009-010434-22-DKChiesi Farmaceutici S.p.A.